Somewhat Favorable News Coverage Somewhat Unlikely to Affect Stellar Biotechnologies (SBOT) Stock Price
News coverage about Stellar Biotechnologies (NASDAQ:SBOT) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Stellar Biotechnologies earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.5174022548273 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Stellar Biotechnologies (NASDAQ:SBOT) traded up 2.61% during trading on Monday, hitting $1.18. The stock had a trading volume of 828 shares. The company’s market cap is $12.41 million. Stellar Biotechnologies has a 12-month low of $1.05 and a 12-month high of $3.00. The stock’s 50 day moving average is $1.30 and its 200-day moving average is $1.42.
Stellar Biotechnologies (NASDAQ:SBOT) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.12) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.12). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.34 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. Analysts forecast that Stellar Biotechnologies will post ($0.47) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/21/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-stellar-biotechnologies-sbot-stock-price.html.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases.
Receive News & Stock Ratings for Stellar Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stellar Biotechnologies Inc. and related stocks with our FREE daily email newsletter.